Celloram, Inc.
Celloram Inc. is a Cleveland-based biotech startup dedicated to developing innovative medicines for cancer and immune disorders. The company focuses on cellular immunotherapy and small molecule therapeutics, aiming to revolutionize patient care with safer and more effective treatments. With a team of experienced scientists and strategic partnerships, Celloram is advancing its product pipeline towards clinical development and commercialization. The company is also actively engaged in licensing agreements, such as with GENFIT SA, to expand its therapeutic platform into liver disease indications. Celloram's mission is to harness the power of the immune system to create transformative therapies that prevent disease and promote healing, driven by a vision to be a global leader in human health improvement.
Industries
Nr. of Employees
small (1-50)
Celloram, Inc.
11000 Cedar Ave. 100F #23, Cleveland, OH 44106
Products
CLM-022 (inflammasome inhibitor program)
Preclinical small-molecule program targeting NLRP3 inflammasome priming and activation; demonstrated in vitro suppression of IL-1β/IL-18 and pyroptosis in human immune cells and in vivo protection in rodent liver-injury and endotoxemia models following oral and intravenous dosing. The program has been out-licensed to an external development partner for liver disease indications.
NOVS-100 (FABP inhibitor program)
Preclinical small-molecule program focused on inhibition of fatty acid–binding proteins to modulate lipid metabolism and tumor microenvironment biology, intended for oncology and metabolic disease research.
Personalized dendritic cell vaccine workflow (Protexi)
Personalized cancer vaccine workflow that integrates tumor genomic sequencing, computational neoantigen prediction, and ex vivo expanded autologous dendritic cells loaded with patient-specific antigens for immunotherapy development.
CLM-022 (inflammasome inhibitor program)
Preclinical small-molecule program targeting NLRP3 inflammasome priming and activation; demonstrated in vitro suppression of IL-1β/IL-18 and pyroptosis in human immune cells and in vivo protection in rodent liver-injury and endotoxemia models following oral and intravenous dosing. The program has been out-licensed to an external development partner for liver disease indications.
NOVS-100 (FABP inhibitor program)
Preclinical small-molecule program focused on inhibition of fatty acid–binding proteins to modulate lipid metabolism and tumor microenvironment biology, intended for oncology and metabolic disease research.
Personalized dendritic cell vaccine workflow (Protexi)
Personalized cancer vaccine workflow that integrates tumor genomic sequencing, computational neoantigen prediction, and ex vivo expanded autologous dendritic cells loaded with patient-specific antigens for immunotherapy development.
Services
Medicinal chemistry support for design, synthesis, optimization and validation of small-molecule candidates provided to development partners.
Execution of in vitro immunology assays and rodent efficacy studies to generate pharmacology, biomarker and mechanism-of-action data for development candidates.
Tumor genomic sequencing (WES/RNAseq) and computational prediction to identify patient-specific neoantigens and prioritize candidates for vaccine or cell therapy loading.
Production workflows for clinical-grade antigen materials and processed cell therapy inputs under GMP to support early-phase clinical studies.
Ex vivo induction and characterization of tolerogenic dendritic cells for applications in autoimmunity and transplant, with supporting preclinical efficacy studies.
Advisory and transactional support to structure licensing deals, joint development agreements, and transfer of early-stage assets to external development partners, including provision of scientific and chemistry support.
Medicinal chemistry support for design, synthesis, optimization and validation of small-molecule candidates provided to development partners.
Execution of in vitro immunology assays and rodent efficacy studies to generate pharmacology, biomarker and mechanism-of-action data for development candidates.
Tumor genomic sequencing (WES/RNAseq) and computational prediction to identify patient-specific neoantigens and prioritize candidates for vaccine or cell therapy loading.
Production workflows for clinical-grade antigen materials and processed cell therapy inputs under GMP to support early-phase clinical studies.
Ex vivo induction and characterization of tolerogenic dendritic cells for applications in autoimmunity and transplant, with supporting preclinical efficacy studies.
Advisory and transactional support to structure licensing deals, joint development agreements, and transfer of early-stage assets to external development partners, including provision of scientific and chemistry support.
Expertise Areas
- Small-molecule discovery and medicinal chemistry optimization
- Inflammasome (NLRP3) inhibitor discovery and translational development
- Personalized neoantigen identification and selection using WES/RNAseq
- Autologous dendritic cell manufacturing and antigen loading
Key Technologies
- Whole-exome sequencing (WES)
- RNA sequencing (RNAseq)
- Neoantigen prediction algorithms
- Ex vivo dendritic cell expansion and antigen loading
News & Updates
Genfit presented preclinical data on CLM-022, licensed from Celloram, demonstrating its potential as a treatment for liver diseases, including ACLF. The data showed the drug's efficacy in inhibiting NLRP3 inflammasome activity, reducing liver damage and systemic inflammation in animal models.
Genfit showcased preclinical studies demonstrating the capacity of CLM-022 to suppress inflammasome formation, reduce IL-1β secretion, and mitigate pyroptosis, highlighting its potential as a therapy for ACLF.
Celloram announced a licensing agreement with Genfit, granting exclusive global rights to develop CLM-022 for liver diseases. The collaboration aims to advance this first-in-class NLRP3 inflammasome inhibitor towards clinical trials.
Genfit presented preclinical data on CLM-022, licensed from Celloram, demonstrating its potential as a treatment for liver diseases, including ACLF. The data showed the drug's efficacy in inhibiting NLRP3 inflammasome activity, reducing liver damage and systemic inflammation in animal models.
Genfit showcased preclinical studies demonstrating the capacity of CLM-022 to suppress inflammasome formation, reduce IL-1β secretion, and mitigate pyroptosis, highlighting its potential as a therapy for ACLF.
Celloram announced a licensing agreement with Genfit, granting exclusive global rights to develop CLM-022 for liver diseases. The collaboration aims to advance this first-in-class NLRP3 inflammasome inhibitor towards clinical trials.